These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 8767349)
1. Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Kondo T; Yoshida K; Yoshimura Y; Motohashi M; Tanayama S Arzneimittelforschung; 1996 Jun; 46(6):594-600. PubMed ID: 8767349 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. Hübner R; Högemann AM; Sunzel M; Riddell JG J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000 [TBL] [Abstract][Full Text] [Related]
3. Disposition of the new antirheumatic agent ethyl 4-(3,4-dimethoxyphenyl)- 6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603) in rats and dogs. Tagawa Y; Kiyota Y; Yoshimura Y; Motohashi M; Tanayama S Arzneimittelforschung; 1998 Jul; 48(7):750-7. PubMed ID: 9706376 [TBL] [Abstract][Full Text] [Related]
4. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Maeshiba Y; Kiyota Y; Yamashita K; Yoshimura Y; Motohashi M; Tanayama S Arzneimittelforschung; 1997 Jan; 47(1):29-35. PubMed ID: 9037440 [TBL] [Abstract][Full Text] [Related]
5. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys. Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675 [TBL] [Abstract][Full Text] [Related]
6. Characterization of conjugated metabolites of a new angiotensin II receptor antagonist, candesartan cilexetil, in rats by liquid chromatography/electrospray tandem mass spectrometry following chemical derivatization. Kondo T; Yoshida K; Yoshimura Y; Motohashi M; Tanayama S J Mass Spectrom; 1996 Aug; 31(8):873-8. PubMed ID: 8799313 [TBL] [Abstract][Full Text] [Related]
7. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs. Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117 [TBL] [Abstract][Full Text] [Related]
9. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats. Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442 [TBL] [Abstract][Full Text] [Related]
10. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions. Kito G; Ito K; Shiomi M Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337 [TBL] [Abstract][Full Text] [Related]
11. Differences among angiotensin II type 1 receptor blockers: characteristics of candesartan cilexetil. Unger T Blood Press Suppl; 2000; 1():14-8. PubMed ID: 11059630 [TBL] [Abstract][Full Text] [Related]
12. Disposition of a new nonsteroidal anti-inflammatory agent, S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid, in rats, dogs and monkeys. Konishi T; Okada S; Nishikawa H; Esumi Y; Kitamura S; Tatsumi K Arzneimittelforschung; 1998 Mar; 48(3):266-74. PubMed ID: 9553685 [TBL] [Abstract][Full Text] [Related]
13. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil. Naka T; Kubo K; Inada Y; Nishikawa K Drug Des Discov; 1999 Aug; 16(2):95-108. PubMed ID: 10533806 [TBL] [Abstract][Full Text] [Related]
14. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. Elmfeldt D; George M; Hübner R; Olofsson B J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007 [TBL] [Abstract][Full Text] [Related]
15. Disposition of TAK-044, a new endothelin antagonist, in rats and dogs. Maeshiba Y; Takeuchi T; Kondo T; Yamashita K; Tsukuda R; Yoshimura Y Arzneimittelforschung; 2002; 52(8):587-92. PubMed ID: 12236045 [TBL] [Abstract][Full Text] [Related]
16. Disposition of the angiotensin II receptor antagonist L-158,809 in rats and rhesus monkeys. Colletti AE; Krieter PA Drug Metab Dispos; 1994; 22(2):183-8. PubMed ID: 8013272 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man. Malerczyk C; Fuchs B; Belz GG; Roll S; Butzer R; Breithaupt-Grögler K; Herrmann V; Magin SG; Högemann A; Voith B; Mutschler E Br J Clin Pharmacol; 1998 Jun; 45(6):567-73. PubMed ID: 9663812 [TBL] [Abstract][Full Text] [Related]
18. Absorption, plasma concentration, and excretion after single administration of 14C-(+-)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5- nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate hydrochloride in rats and dogs. Matsunaga T; Tanabe H; Mochizuki T; Okabe K; Arizono H; Taneda M; Sato H; Ishii S; Sato J; Kiyoki M Arzneimittelforschung; 1992 Apr; 42(4):519-25. PubMed ID: 1642676 [TBL] [Abstract][Full Text] [Related]
19. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. Sever P J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018 [TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. Brilla CG; Scheer C; Rupp H J Hypertens Suppl; 1997 Dec; 15(6):S13-9. PubMed ID: 9493122 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]